Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.
Blood|July 12, 2019
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemiaBrian Giacopelli, Qiuhong Zhao, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The British Journal of Dermatology|January 10, 2018
Towards an international language for incontinence-associated dermatitis (IAD): design and evaluation of psychometric properties of the Ghent Global IAD Categorization Tool (GLOBIAD) in 30 countriesD Beeckman, K Van den Bussche, P Alves, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
Pageof 19